Negative impact of chronic obstructive pulmonary disease on the health-related quality of life of patients.: Results of the EPIDEPOC study

被引:126
作者
Carrasco Garrido, Pilar
de Miguel Diez, Javier
Rejas Gutierrez, Javier
Martin Centeno, Antonio
Gobartt Vazquez, Elena
Gil de Miguel, Angel
Garcia Carballo, Marta
Jimenez Garcia, Rodrigo
机构
[1] Pfizer Espana, Med Unit, Dept Hlth Outcomes Res, Madrid 28108, Spain
[2] Univ Rey Juan Carlos, Prevent Med & Publ Hlth Dept, Madrid, Spain
[3] Univ Hosp Gregorio Maranon, Dept Pneumol, Madrid, Spain
[4] Pfizer Espana, Med Unit, Resp Area, Madrid, Spain
[5] Boehringer Ingelheim SA, Dept Med, Barcelona, Spain
关键词
D O I
10.1186/1477-7525-4-31
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: COPD is currently the fourth cause of morbidity and mortality in the developed world. Patients with COPD experience a progressive deterioration and disability, which lead to a worsening in their health-related quality of life (HRQoL). The aim of this work is to assess the Health-Related Quality of Life ( HRQoL) of patients with stable COPD followed in primary care and to identify possible predictors of disease. Methods: It is a multicenter, epidemiological, observational, descriptive study. Subjects of both sexes, older than 40 years and diagnosed of COPD at least 12 months before starting the study were included. Sociodemographic data, severity of disease, comorbidity, and use of health resources in the previous 12 months were collected. All patients were administered a generic quality-of-life questionnaire, the SF-12, that enables to calculate two scores, the physical (PCS-12) and the mental (MCS-12) component summary scores. Results: 10,711 patients were evaluated (75.6% men, 24.4% women), with a mean age of 67.1 years (SD 9.66). The mean value of FEV1 was 35.9 +/- 10.0%. Mean PCS-12 and MCS-12 scores were 36.0 +/- 9.9 and 48.3 +/- 10.9, respectively. Compared to the reference population, patients with COPD had a reduction of PCS-12, even in mild stages of the disease. The correlation with FEV1 was higher for PCS-12 ( r = 0.38) than for MCS-12 ( r = 0.12). Predictors for both HRQoL components were sex, FEV1, use of oxygen therapy, and number of visits to emergency rooms and hospital admissions. Other independent predictors of PCS-12 were age, body mass index and educational level. Conclusion: Patients with stable COPD show a reduction of their HRQoL, even in mild stages of the disease. The factors determining the HRQoL include sex, FEV1, use of oxygen therapy, and number of visits to emergency rooms and hospital admissions.
引用
收藏
页数:9
相关论文
共 43 条
[1]   Mortality after hospitalization for COPD [J].
Almagro, P ;
Calbo, E ;
de Echagüen, AO ;
Barreiro, B ;
Quintana, S ;
Heredia, JL ;
Garau, J .
CHEST, 2002, 121 (05) :1441-1448
[2]   Guidelines for care of the patient with chronic obstructive pulmonary disease [J].
Alvarez-Sala, JL ;
Cimas, E ;
Masa, JF ;
Miravitlles, M ;
Molina, J ;
Naberan, K ;
Simonet, P ;
Viejo, JL .
ARCHIVOS DE BRONCONEUMOLOGIA, 2001, 37 (07) :269-278
[3]   ANTIBIOTIC-THERAPY IN EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY-DISEASE [J].
ANTHONISEN, NR ;
MANFREDA, J ;
WARREN, CPW ;
HERSHFIELD, ES ;
HARDING, GKM ;
NELSON, NA .
ANNALS OF INTERNAL MEDICINE, 1987, 106 (02) :196-204
[4]   Clinical guidelines for diagnosing and treating chronic obstructive pulmonary disease [J].
Barberà, JA ;
Peces-Barba, G ;
Agustí, AGN ;
Izquierdo, JL ;
Monsó, E ;
Montemayor, T ;
Viejo, JL .
ARCHIVOS DE BRONCONEUMOLOGIA, 2001, 37 (06) :297-316
[5]   Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial [J].
Burge, PS ;
Calverley, PMA ;
Jones, PW ;
Spencer, S ;
Anderson, JA ;
Maslen, TK .
BMJ-BRITISH MEDICAL JOURNAL, 2000, 320 (7245) :1297-1303
[6]   COURSE AND PROGNOSIS OF CHRONIC OBSTRUCTIVE LUNG DISEASE - A PROSPECTIVE STUDY OF 200 PATIENTS [J].
BURROWS, B ;
EARLE, RH .
NEW ENGLAND JOURNAL OF MEDICINE, 1969, 280 (08) :397-&
[7]   Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper [J].
Celli, BR ;
MacNee, W ;
Agusti, A ;
Anzueto, A ;
Berg, B ;
Buist, AS ;
Calverley, PMA ;
Chavannes, N ;
Dillard, T ;
Fahy, B ;
Fein, A ;
Heffner, J ;
Lareau, S ;
Meek, P ;
Martinez, F ;
McNicholas, W ;
Muris, J ;
Austegard, E ;
Pauwels, R ;
Rennard, S ;
Rossi, A ;
Siafakas, N ;
Tiep, B ;
Vestbo, J ;
Wouters, E ;
ZuWallack, R .
EUROPEAN RESPIRATORY JOURNAL, 2004, 23 (06) :932-946
[8]   Outcomes following acute exacerbation of severe chronic obstructive lung disease [J].
Connors, AF ;
Dawson, NV ;
Thomas, C ;
Harrell, FE ;
Desbiens, N ;
Fulkerson, WJ ;
Kussin, P ;
Bellamy, P ;
Goldman, L ;
Knaus, WA .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1996, 154 (04) :959-967
[9]  
Díez JD, 2004, ARCH BRONCONEUMOL, V40, P431
[10]   Health-related QOL in acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease: A review of the literature [J].
Doll, H ;
Miravitlles, M .
PHARMACOECONOMICS, 2005, 23 (04) :345-363